Pinned post
I am glad to share our latest work on NECTIN-4 expression in urothelial cancer published in @CCR_AACR. The current use of enfortumab vedotin requires critical re-evaluation. Further, we highlight the importance of repeated metastatic biopsies! Thanks to all collaborators!
Happy to share our work: Membranous NECTIN-4 expression frequently decreases during metastatic spread of urothelial carcinoma and is associated with enfortumab vedotin resistance @CCR_AACR aacrjournals.org/clincancerres/… Follow our tweetorial about this clinically important data 1/12View quoted post on X